Background: In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study was to evaluate the effect of prophylaxis with palivizumab in preventing RSV-associated hospitalization in infants with CHD.
Methods: We carried out an observational, retrospective study in a paediatric cardiology division at a secondary-care centre in Italy, extracting from the database children with CHD who, from November 2004 to March 2022, matched the criteria for palivizumab prophylaxis, to evaluate the hospitalization rate in CHD patients with and without palivizumab prophylaxis and their RSV-related hospitalization characteristics compared with a group of children without CHD and no other underlying clinical conditions (control group, CG), hospitalized for RSV infection.
Results: One hundred twenty-eight children with CHD were enrolled in the study, mainly (71.9%) with increased pulmonary flow, and received palivizumab prophylaxis. Twenty-seven received hospital care for bronchiolitis. Almost all CHD patients hospitalized for bronchiolitis (26 out of 27) received partial prophylaxis (≤ 3 doses). CHD patients with bronchiolitis stay longer in the hospital than control (14.4 ± 21.7 days vs 6.2 ± 2.3 days) some of which require intensive care (n = 4).
Conclusions: Our study provides evidence of the efficacy of palivizumab in protecting patients with hemodynamically significant CHD under the age of 2 years from RSV disease and its life-threatening complications. Reducing hospitalisation rate, morbidity, and mortality in this category of patients, passive immune prophylaxis with palivizumab may impact healthcare resource availability and utilisation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835345 | PMC |
| http://dx.doi.org/10.1186/s13052-022-01399-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolving Strategies for Respiratory Syncytial Virus (RSV): A Review Article of Preventive Agents and Vaccines for RSV.
Ann Pharmacother
January 2025
ForHealth Consulting, UMass Chan Medical School, Shrewsbury, MA, USA.
Objective: The objective was to describe the pharmacology, efficacy, safety, and recommendations for the use of newly approved preventive agents and vaccines for respiratory syncytial virus (RSV) and discuss their uptake during the 2023 to 2024 RSV season.
Data Sources: A literature search of PubMed was performed (January 2020 to February 2024) with the search terms RSV vaccine, preventive antibody, and RSV prevention. Utilization data were collected from TriNetX using the US Collaborative Network (May 2024) using the terms palivizumab, nirsevimab, and RSV prefusion F protein.
Trends in endemic of respiratory syncytial virus infection during COVID-19 pandemic and difficulty in obtaining optimal timing of palivizumab prophylaxis.
J Infect Chemother
December 2024
Department of Pediatrics, School of Medicine, University of Occupational and Environmental Health, , Kitakyushu, Japan; General Medical Department, Fukuoka Children's Hospital, Fukuoka, Japan. Electronic address:
Objective: The coronavirus disease (COVID-19) pandemic has affected the epidemiology of respiratory syncytial virus (RSV) infection. This study assessed whether or not palivizumab prophylaxis was appropriate during the COVID-19 pandemic.
Methods: This prospective study included children <24 months old who were hospitalized for RSV infection between April 2019 and March 2023.
[Not Available].
Can Fam Physician
December 2024
Conseillère médicale principale au Centre de surveillance et des programmes d'immunisation à l'Agence de la santé publique du Canada, professeure agrégée à la Section des allergies et de l'immunologie clinique du Département de pédiatrie à l'Université du Manitoba à Winnipeg, et professeure adjointe à la Division des allergies et de l'immunologie du Département de pédiatrie de l'Université de la Colombie-Britannique à Vancouver.
Approach to prevention of respiratory syncytial virus disease in infants by passive immunization.
Can Fam Physician
December 2024
Senior Medical Advisor in the Centre for Immunization Surveillance and Programs at the Public Health Agency of Canada, Associate Professor in the Department of Pediatrics in the Section of Allergy and Clinical Immunology at the University of Manitoba in Winnipeg, and Adjunct Professor in the Department of Pediatrics in the Division of Allergy and Immunology at the University of British Columbia in Vancouver.
Article Synopsis
- The objective is to help family physicians effectively discuss RSV immunizations with their patients.
- There are three preventive options for severe RSV disease in infants: palivizumab for high-risk infants, nirsevimab for all infants, and the RSVpreF vaccine for pregnant individuals.
- Family doctors need to understand each immunization option's specifics, including recommendations and patient considerations, to support informed choices for parents and infants.
The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma.
Vaccines (Basel)
November 2024
The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel.
Background: The respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and is associated with an increased risk of asthma development. Palivizumab, an RSV prophylactic, reduces RSV-related hospitalizations in high-risk infants, but its impact on long-term asthma outcomes remains unclear. This study compares asthma-related healthcare utilization in preschool children born prematurely between those who received Palivizumab (the Prophylaxis (+) group) and those who did not (the Prophylaxis (-) group).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!